bit.bio's CEO, our cell programming approach and our products prominently covered in synthetic biology article.
04.03.2024
bit.bio's CEO, our cell programming approach and our products prominently covered in synthetic biology article.
04.03.2024 Published by Genetic Engineering & Biotechnology News
Reprogramming Stars - featuring bit.bio CEO Mark Kotter
Editor-in-Chief Carlos-Filipe Pereira interviews our CEO for the Reprogramming Stars series in the journal Cellular Reprogramming.
bit.bio cell therapy pipeline featured in Endpoints News
Endpoints News did an exclusive interview with bit.bio's CEO after the cell therapy pipeline announcement with an initial focus on...
bit.bio named as one of the WIRED Trailblazers in Cambridge
WIRED have named 16 Trailblazer companies in Cambridge that are pushing boundaries and scaling up - including bit.bio.
Five things you need to succeed as a leader - Authority Magazine Q&A
Authority Magazine interviewed bit.bio's SVP of tech ops and manufacturing Kathryn Golden to discover her path to leadership and w...
Navigating the future of cell therapies with exec Kathryn Corzo
Our President and COO Kathryn Corzo talks with editor Brian Buntz from Drug Discovery & Development.
The UK has the chance to lead the way in synbio. We must grasp it.
An article on synbio in the Summer 2023 issue of Science in Parliament magazine. Authored by our founder and CEO Mark Kotter.
Synthetic biology: impacting drug discovery
Our CEO Mark Kotter talks to Drug Discovery World about different approaches to synthetic biology and its applications in drug dis...
proto.life feature on industrial manufacture of human cells
This in depth feature covers bit.bio's breakthrough reprogramming approach and ability to manufacture human cells at industrial sc...
Loading form…